Temsirolimus inhibits proliferation and migration in retinal pigment epithelial and endothelial cells via mTOR inhibition and decreases VEGF and PDGF expression.
Due to their high prevalence, retinal vascular diseases including age related macular degeneration (AMD), retinal vein occlusions (RVO), diabetic retinopathy (DR) and diabetic macular edema have been major therapeutic targets over the last years. The pathogenesis of these diseases is complex and yet...
Main Authors: | Raffael Liegl, Susanna Koenig, Jakob Siedlecki, Christos Haritoglou, Anselm Kampik, Marcus Kernt |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3935828?pdf=render |
Similar Items
-
Triggering of Eryptosis, the Suicidal Erythrocyte Death by Mammalian Target of Rapamycin (mTOR) inhibitor Temsirolimus
by: Abdulla Al Mamun Bhuyan, et al.
Published: (2017-07-01) -
A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies
by: Neel D. Trivedi, et al.
Published: (2021-03-01) -
Hyperglycemia-induced VEGF and ROS production in retinal cells is inhibited by the mTOR inhibitor, rapamycin
by: Teruyo Kida, et al.
Published: (2021-01-01) -
Comparative evaluation of combined navigated laser photocoagulation and intravitreal ranibizumab in the treatment of diabetic macular edema.
by: Raffael Liegl, et al.
Published: (2014-01-01) -
Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.
by: Wei-Xiang Qi, et al.
Published: (2013-01-01)